Protagonist Therapeutics announced detailed clinical study results for icotrokinra, highlighting its potential to transform the treatment paradigm for plaque psoriasis. Data from the Phase 3 ICONIC-LEAD study showed nearly half of patients (46%) with moderate-to-severe plaque psoriasis achieved completely clear skin (IGA 0) at Week 24.
Topline results from the Phase 3 ICONIC-ADVANCE 1&2 studies demonstrated that icotrokinra met its co-primary endpoints of IGA 0/1 and PASI 90 versus placebo at Week 16. Critically, these studies also showed superiority to Bristol-Myers Squibb & Co’s Sotyktu (deucravacitinib) in patients with moderate-to-severe plaque psoriasis.
The ongoing ICONIC-ASCEND trial is a pioneering head-to-head study against the injectable biologic ustekinumab, aiming to further demonstrate the superiority of this oral pill. These results underscore icotrokinra's strong efficacy and competitive profile in the plaque psoriasis market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.